Literature DB >> 22997201

Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors.

Mark W Kieran1, Charles W M Roberts, Susan N Chi, Keith L Ligon, Benjamin E Rich, Laura E Macconaill, Levi A Garraway, Jaclyn A Biegel.   

Abstract

BACKGROUND: Rhabdoid tumors (also called atypical teratoid/rhabdoid tumor (AT/RT) in the brain), are highly malignant, poor prognosis lesions arising in the kidneys, soft tissues, and central nervous system. Targeted therapy in this disease would benefit from advanced technologies detecting relevant actionable mutations. PROCEDURE: Here we report on the evaluation of 25 tumors, all with known SMARCB1/INI1 alterations, for the presence of 983 different mutations in 115 oncogenes and tumor-suppressor genes using OncoMap, a mass spectrometric method of allele detection.
RESULTS: Other than mutations in SMARCB1, our results identified a single activating mutation in NRAS and complete absence of oncogenic mutations in all other genes tested.
CONCLUSION: The absence of mutations in canonical pathways critical for development and progression of adult cancers suggests that distinct mechanisms drive these highly malignant pediatric tumors. This may limit the therapeutic utility of available targeted therapies and require a refocusing toward developmental and epigenetic pathways.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22997201      PMCID: PMC3538080          DOI: 10.1002/pbc.24315

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  25 in total

Review 1.  INI1-deficient tumors: diagnostic features and molecular genetics.

Authors:  Travis J Hollmann; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

2.  High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival.

Authors:  Diane K Birks; Andrew M Donson; Purvi R Patel; Christopher Dunham; Andrea Muscat; Elizabeth M Algar; David M Ashley; B K Kleinschmidt-Demasters; Rajeev Vibhakar; Michael H Handler; Nicholas K Foreman
Journal:  Neuro Oncol       Date:  2011-09-23       Impact factor: 12.300

3.  Molecular genetic alterations and gene expression profile of a malignant rhabdoid tumor of the kidney.

Authors:  Toshihito Nagata; Yasuo Takahashi; Yukimoto Ishii; Satoshi Asai; Megumi Sugahara-Kobayashi; Yayoi Nishida; Akiko Murata; Shunji Yamamori; Yoshiyasu Ogawa; Takeshi Nakamura; Hitohiko Murakami; Masanori Nakamura; Hiroyuki Shichino; Motoaki Chin; Kiminobu Sugito; Taro Ikeda; Tsugumichi Koshinaga; Hideo Mugishima
Journal:  Cancer Genet Cytogenet       Date:  2005-12

4.  hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities.

Authors:  F Bourdeaut; P Fréneaux; B Thuille; A Lellouch-Tubiana; A Nicolas; J Couturier; G Pierron; C Sainte-Rose; C Bergeron; R Bouvier; X Rialland; V Laurence; J Michon; X Sastre-Garau; O Delattre
Journal:  J Pathol       Date:  2007-02       Impact factor: 7.996

5.  High-throughput oncogene mutation profiling in human cancer.

Authors:  Roman K Thomas; Alissa C Baker; Ralph M Debiasi; Wendy Winckler; Thomas Laframboise; William M Lin; Meng Wang; Whei Feng; Thomas Zander; Laura MacConaill; Laura E Macconnaill; Jeffrey C Lee; Rick Nicoletti; Charlie Hatton; Mary Goyette; Luc Girard; Kuntal Majmudar; Liuda Ziaugra; Kwok-Kin Wong; Stacey Gabriel; Rameen Beroukhim; Michael Peyton; Jordi Barretina; Amit Dutt; Caroline Emery; Heidi Greulich; Kinjal Shah; Hidefumi Sasaki; Adi Gazdar; John Minna; Scott A Armstrong; Ingo K Mellinghoff; F Stephen Hodi; Glenn Dranoff; Paul S Mischel; Tim F Cloughesy; Stan F Nelson; Linda M Liau; Kirsten Mertz; Mark A Rubin; Holger Moch; Massimo Loda; William Catalona; Jonathan Fletcher; Sabina Signoretti; Frederic Kaye; Kenneth C Anderson; George D Demetri; Reinhard Dummer; Stephan Wagner; Meenhard Herlyn; William R Sellers; Matthew Meyerson; Levi A Garraway
Journal:  Nat Genet       Date:  2007-02-11       Impact factor: 38.330

6.  Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors.

Authors:  Eric M Jackson; Angela J Sievert; Xiaowu Gai; Hakon Hakonarson; Alexander R Judkins; Laura Tooke; Juan Carlos Perin; Hongbo Xie; Tamim H Shaikh; Jaclyn A Biegel
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

7.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Authors:  Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

8.  Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability.

Authors:  Elizabeth S McKenna; Courtney G Sansam; Yoon-Jae Cho; Heidi Greulich; Julia A Evans; Christopher S Thom; Lisa A Moreau; Jaclyn A Biegel; Scott L Pomeroy; Charles W M Roberts
Journal:  Mol Cell Biol       Date:  2008-08-18       Impact factor: 4.272

9.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

10.  Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor.

Authors:  Susan N Chi; Mary Ann Zimmerman; Xiaopan Yao; Kenneth J Cohen; Peter Burger; Jaclyn A Biegel; Lucy B Rorke-Adams; Michael J Fisher; Anna Janss; Claire Mazewski; Stewart Goldman; Peter E Manley; Daniel C Bowers; Anne Bendel; Joshua Rubin; Christopher D Turner; Karen J Marcus; Liliana Goumnerova; Nicole J Ullrich; Mark W Kieran
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

View more
  26 in total

Review 1.  Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies.

Authors:  Michael C Frühwald; Jaclyn A Biegel; Franck Bourdeaut; Charles W M Roberts; Susan N Chi
Journal:  Neuro Oncol       Date:  2016-01-10       Impact factor: 12.300

Review 2.  Diffuse intrinsic pontine glioma: a reassessment.

Authors:  Nathan J Robison; Mark W Kieran
Journal:  J Neurooncol       Date:  2014-05-03       Impact factor: 4.130

3.  Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.

Authors:  Cynthia Wetmore; James Boyett; Shaoyu Li; Tong Lin; Anne Bendel; Amar Gajjar; Brent A Orr
Journal:  Neuro Oncol       Date:  2015-02-16       Impact factor: 12.300

4.  Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.

Authors:  Isabel Tegeder; Katharina Thiel; Serap Erkek; Pascal D Johann; Johannes Berlandi; Venu Thatikonda; Michael C Frühwald; Marcel Kool; Astrid Jeibmann; Martin Hasselblatt
Journal:  J Neurooncol       Date:  2018-11-16       Impact factor: 4.130

5.  Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma.

Authors:  Irene Paganini; Gabriele Lorenzo Capone; Jeremie Vitte; Roberta Sestini; Anna Laura Putignano; Marco Giovannini; Laura Papi
Journal:  J Neurooncol       Date:  2017-12-11       Impact factor: 4.130

6.  Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.

Authors:  Marina N Nikiforova; Abigail I Wald; Melissa A Melan; Somak Roy; Shan Zhong; Ronald L Hamilton; Frank S Lieberman; Jan Drappatz; Nduka M Amankulor; Ian F Pollack; Yuri E Nikiforov; Craig Horbinski
Journal:  Neuro Oncol       Date:  2015-12-17       Impact factor: 12.300

7.  MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.

Authors:  Thomas P Howard; Taylor E Arnoff; Melinda R Song; Andrew O Giacomelli; Xiaofeng Wang; Andrew L Hong; Neekesh V Dharia; Su Wang; Francisca Vazquez; Minh-Tam Pham; Ann M Morgan; Franziska Wachter; Gregory H Bird; Guillaume Kugener; Elaine M Oberlick; Matthew G Rees; Hong L Tiv; Justin H Hwang; Katherine H Walsh; April Cook; John M Krill-Burger; Aviad Tsherniak; Prafulla C Gokhale; Peter J Park; Kimberly Stegmaier; Loren D Walensky; William C Hahn; Charles W M Roberts
Journal:  Cancer Res       Date:  2019-02-12       Impact factor: 12.701

Review 8.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

Review 9.  Misactivation of Hedgehog signaling causes inherited and sporadic cancers.

Authors:  David R Raleigh; Jeremy F Reiter
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

10.  Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.

Authors:  Anjali Singh; Xueqing Lun; Aarthi Jayanthan; Halah Obaid; Yibing Ruan; Douglas Strother; Susan N Chi; Amy Smith; Peter Forsyth; Aru Narendran
Journal:  Mol Oncol       Date:  2013-01-11       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.